Acro Biomedical Co., Ltd.
ACBM
$0.0007
-$0.1043-99.33%
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -59.84% | -74.22% | -45.01% | 49.54% | 49.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.84% | -74.22% | -45.01% | 49.54% | 49.54% |
| Cost of Revenue | -55.82% | -72.84% | -44.78% | 36.73% | 36.73% |
| Gross Profit | -71.74% | -79.12% | -45.86% | 106.85% | 106.85% |
| SG&A Expenses | 8.61% | 45.79% | 122.28% | 369.90% | 1,036.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.03% | 25.79% | 85.90% | 269.28% | 879.66% |
| Operating Income | -2.54% | -37.87% | -106.27% | -302.90% | -1,377.57% |
| Income Before Tax | -2.55% | -37.87% | -106.18% | -302.29% | -1,366.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.55% | -37.87% | -106.18% | -304.15% | -1,393.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.55% | -37.87% | -106.18% | -304.15% | -1,393.18% |
| EBIT | -2.54% | -37.87% | -106.27% | -302.90% | -1,377.57% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.41% | -34.28% | -97.83% | -271.33% | -1,162.44% |
| Normalized Basic EPS | -1.48% | -34.28% | -97.73% | -269.44% | -1,134.13% |
| EPS Diluted | -1.41% | -31.42% | -91.66% | -250.07% | -936.25% |
| Normalized Diluted EPS | -1.30% | -36.15% | -101.83% | -284.11% | -1,120.63% |
| Average Basic Shares Outstanding | 1.31% | 5.55% | 11.57% | 18.40% | 22.33% |
| Average Diluted Shares Outstanding | 1.68% | 4.20% | 10.07% | 16.70% | 23.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
